Dosing recommendations for biphasic insulin aspart 30 (BIAsp30), insulin detemir (lDet) and insulin aspart (IAsp) from the PREFER treat-to-target study

被引：0
|
作者：
Liebl, A.
Compion, G.
Prager, R.
Binz, K.
Kaiser, M.
Gallwitz, B.
机构：
[1] Ctr Diabet & Metab, Bad Heilbrunn, Germany
[2] Novo Nordisk Ltd, Crawley, England
[3] Inst Metab Dis & Nutr, Med Abt Stoffwechselerkrankungen & Nephrol, Vienna, Austria
[4] Triemli City Hosp, Dept Endocrinol & Diabet, Zurich, Switzerland
[5] Novo Nordisk Pharma GmbH, Dept Diabet, Mainz, Germany
[6] Univ Tubingen, Med Klin 4, Tubingen, Germany
来源：
DIABETIC MEDICINE | 2007年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：75 / 75
页数：1
相关论文
共 50 条
  • [21] IMPROVE study: initiation of biphasic insulin BIAsp30 in type 2 diabetics
    Valensi, Paul
    METABOLISMES HORMONES DIABETES ET NUTRITION, 2008, 12 (06): : 222 - 223
  • [22] Insulin degludec/insulin aspart versus biphasic insulin aspart 30 twice daily in insulin-experienced Japanese subjects with uncontrolled type 2 diabetes: Subgroup analysis of a Pan-Asian, treat-to-target Phase 3 Trial
    Taneda, Shinji
    Hyllested-Winge, Jacob
    Gall, Mari-Anne
    Kaneko, Shizuka
    Hirao, Koichi
    JOURNAL OF DIABETES, 2017, 9 (03) : 243 - 247
  • [23] Pharmacokinetic and pharmacodynamic differences between premixed suspensions of insulin aspart: biphasic insulin aspart 30, 50 and 70
    Heise, T
    Kapitza, C
    Jacobsen, LV
    Brondsted, L
    Heinemann, L
    DIABETOLOGIA, 2005, 48 : A301 - A301
  • [24] Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: A 26-week, randomised, treat-to-target trial
    Kaneko, Shizuka
    Chow, Francis
    Choi, Dong Seop
    Taneda, Shinji
    Hirao, Koichi
    Park, Yongsoo
    Andersen, Thomas Hasseriis
    Gall, Mari-Anne
    Christiansen, Jens Sandahl
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2015, 107 (01) : 139 - 147
  • [25] A Comparison of Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30, 50, 70 and Pure Insulin Aspart: A Randomized, Quadruple Crossover Study
    Thorisdottir, Rannveig Linda
    Parkner, Tina
    Chen, Jian-Wen
    Ejskjaer, Niels
    Christiansen, Jens Sandahl
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 104 (03) : 216 - 221
  • [26] The PREFER study:: both biphasic insulin aspart 30 twice-daily and basal-bolus using insulin detemir and insulin aspart enabled patients with type 2 diabetes to achieve HbA1c target<7.0%
    Liebl, A.
    Prager, R.
    Kaiser, M.
    Binz, K.
    Gailwitz, B.
    DIABETOLOGIA, 2006, 49 : 610 - 611
  • [27] Biphasic insulin aspart 30 as insulin initiation or replacement therapy: the China cohort of the IMPROVE study
    Yang, Wenying
    Gao, Yan
    Liu, Guoliang
    Chen, Lulu
    Fu, Zuzhi
    Zou, Dajin
    Feng, Ping
    Zhao, Zhigang
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (01) : 101 - 107
  • [28] Biphasic insulin aspart 30 improves postprandial glycemic control
    Hermansen, K
    Vaaler, S
    Madsbad, S
    Dalgaard, M
    Begtrup, K
    Lindholm, A
    DIABETES, 2001, 50 : A95 - A95
  • [29] Insulin Degludec/Insulin Aspart (IDegAsp) Provides Superior FPG Control and Reduced Hypoglycaemia vs. Biphasic Insulin Aspart 30 (BIAsp 30) in Insulin-Naive Adults with Type 2 Diabetes in a Randomized Phase 3 Trial
    Franek, Edward
    Haluzik, Martin
    Canecki-Varzic, Silvija
    Sargin, Mehmet
    Macura, Stanislava
    Zacho, Jeppe
    Christiansen, Jens Sandahl
    DIABETES, 2014, 63 : A225 - A225
  • [30] A comparison of pharmocodynamics and pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 & Pure Insulin Aspart in type 1 diabetes
    Thorisdottir, Rannveig L.
    Parkner, Tina
    Chen, Jian-Wen
    Ejskjaer, Niels
    Christiansen, Jens S.
    DIABETES, 2007, 56 : A555 - A555
12345